{"id":62281,"date":"2025-12-01T19:02:29","date_gmt":"2025-12-01T18:02:29","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/psma-targeted-therapy-radiodiagnostics-competitor-analysis-report-2025-researchandmarkets-com\/"},"modified":"2025-12-01T19:02:29","modified_gmt":"2025-12-01T18:02:29","slug":"psma-targeted-therapy-radiodiagnostics-competitor-analysis-report-2025-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/psma-targeted-therapy-radiodiagnostics-competitor-analysis-report-2025-researchandmarkets-com\/","title":{"rendered":"PSMA-Targeted Therapy & Radiodiagnostics Competitor Analysis Report 2025 – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Competitor Analysis: PSMA-Targeted Therapy & Radiodiagnostics”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a>
<\/a><\/p>\n

\nThis competitive intelligence report about PSMA-Targeted Therapies & Radiodiagnostics provides a competitor evaluation in the field of product candidates in research and development targeting prostate-specific membrane antigen (PSMA). The report lists PSMA-targeted R&D programs by R&D phase in a tabular format and describes in brief the profile of PSMA-targeted therapies or radiodiagnostics by drug modality.\n<\/p>\n

\nProstate specific membrane antigen (PSMA) expression is prevalent in prostate cancer, preserved during malignant transformation, and increases in response to anti-androgen therapies, making it a commonly targeted tumor associated antigen for prostate cancer.\n<\/p>\n

\nPSMA mainly serves as a binding target for delivery of a variety of payloads, including, but not limited to, cytotoxic drugs in antibody-drug conjugates, recruitment of cytotoxic T-cells in bispecific antibodies or directly PSMA-targeted chimeric antigen receptor T-cells or natural killer cells.\n<\/p>\n

\nPSMA is also an important binding target for delivery of radioactive payloads in targeted radioligand therapy, whereby binding molecules can be small molecules, peptides and antibodies. A variety of radioligands are being evaluated or have already been approved, including lutetium 177, actinium 225, lead 212, cupper 67, terbium 161, and astatine 211.\n<\/p>\n

\nPSMA-targeting is a clinically validated and increasingly commercially successful approach for positron emission tomography (PET) of prostate cancer and for treatment of PSMA-positive metastatic castration-resistant prostate cancer:<\/strong>\n<\/p>\n